The IGBA has introduced its first global intellectual property and competition report, addressing the urgent need to reform current regulations. But, in a bid to increase access to medicines across the world, did it stop short at just IP and patents?
The International Generic and Biosimilar Medicines Association has released a first-of-its-kind report, delving deep into the nooks and crannies of patent abuse strategies, backed with use cases to illustrate them.
Titled ‘Gaming the system: An overview of originator companies’ evergreening strategies used to hinder access to generic and biosimilar products,” the lengthy 123-page report highlights the different ways originators try...
Formycon said it predicted low earnings in the first quarter of 2025, after enjoying milestone payments last year. Now, the pressure is on the growing biosimilars portfolio to pull the company through this year.
Gedeon Richter’s CEO weighed in on the pricing landscape for biosimilars as the firm admitted the market for biosimilar denosumab was set to be more crowded than it had initially anticipated.
Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.
